Drug Trial Radar · NCT00457457
Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.
Last checked: Nov 19, 2026Latest source record: Dec 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
609
Actual
Start
May 2007
Primary completion
Apr 2008
Study completion Apr 2008
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 6, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 12 week study in which different doses and formulations of UK-369,003 will be administered to patients with a diagnosis of enlarged prostate. Patients will complete a series of questionnaires before, during and after treatment to assess if UK-369,003 has improved their urinary symptoms and erectile function . There will be several blood samples taken during the study to asses the level of drug in the blood and correlate it with the responses to the questionnaires.
Conditions
- Prostatic Hyperplasia
Interventions
TamsulosinDrug
Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate
UK-369,003Drug
UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (\>80 fold) compared to sildenafil (\~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in international prostate symptom scoreTime frame: 12 weeks
Locations
46 sites in 15 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Herston, Queensland, Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Edegem, Belgium
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Pointe-Claire, Quebec, Canada
Pfizer Investigational Site
Santiago, Chile
Pfizer Investigational Site
Temuco, Araucania, Chile
Pfizer Investigational Site
Medellín, Antioquia, Colombia
Pfizer Investigational Site
Barranquilla, Atlántico, Colombia
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Cali, Valle del Cauca Department, Colombia
Pfizer Investigational Site
Aalborg, Denmark
Pfizer Investigational Site
Aarhus N, Denmark
Pfizer Investigational Site
Gentofte Municipality, Denmark
Pfizer Investigational Site
Helsinki, Finland
Pfizer Investigational Site
Kuopio, Finland
Pfizer Investigational Site
Oulu, Finland
Pfizer Investigational Site
Tampere, Finland
Pfizer Investigational Site
Larissa, Greece
Pfizer Investigational Site
Rio, Greece
Pfizer Investigational Site
Thessaloniki, Greece
Pfizer Investigational Site
Foggia, Italy
Pfizer Investigational Site
Siena, Italy
Pfizer Investigational Site
Riga, Latvia
Pfizer Investigational Site
Kaunas, Lithuania
Pfizer Investigational Site
Kaunas, Lithuania
Pfizer Investigational Site
Vilnius, Lithuania
Pfizer Investigational Site
Bydgoszcz, Poland
Pfizer Investigational Site
Bydgoszcz, Poland
Pfizer Investigational Site
Gdansk, Poland
Pfizer Investigational Site
Gdynia, Poland
Pfizer Investigational Site
Mysłowice, Poland
Pfizer Investigational Site
Wejherowo, Poland
Pfizer Investigational Site
Bratislava, Slovakia
Pfizer Investigational Site
Malacky, Slovakia
Pfizer Investigational Site
Nitra, Slovakia
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.